| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR7 |
| Uniprot No | P32248 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-378aa |
| 氨基酸序列 | QDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP |
| 预测分子量 | 41.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CCR7重组蛋白的参考文献，按文献名称、作者和摘要内容概括整理：
---
1. **文献名称**: *"Expression and functional characterization of recombinant human CCR7 in mammalian cells"*
**作者**: Smith A et al.
**摘要**: 本研究通过哺乳动物表达系统成功表达了人源CCR7重组蛋白，并验证其与配体CCL19/CCL21的结合活性及下游信号传导功能，证明其在体外模型中促进T细胞迁移的能力。
---
2. **文献名称**: *"Structural insights into CCR7 extracellular domain recognition by monoclonal antibodies"*
**作者**: Lee J et al.
**摘要**: 利用重组CCR7蛋白的胞外结构域解析其与特异性单克隆抗体的结合表位，揭示了CCR7构象变化对免疫细胞归巢的调控机制，为靶向药物开发提供结构基础。
---
3. **文献名称**: *"Purification and biophysical analysis of CCR7 chemokine receptor for drug screening"*
**作者**: García-Sánchez D et al.
**摘要**: 报道了一种高效纯化重组CCR7蛋白的方法，结合表面等离子共振(SPR)技术筛选小分子抑制剂，证实其在抑制淋巴瘤细胞迁移中的应用潜力。
---
**备注**：以上文献信息为示例性内容，实际引用时需核对真实出版物。建议通过PubMed或Web of Science以关键词“CCR7 recombinant protein”或“CCR7 expression and function”检索最新研究。
**Background of CCR7 Recombinant Protein**
CCR7 (C-C chemokine receptor type 7) is a G protein-coupled receptor (GPCR) that plays a pivotal role in immune cell trafficking and adaptive immunity. It binds to its endogenous ligands, CCL19 and CCL21. which are chemokines expressed in lymphoid tissues. This interaction guides dendritic cells (DCs), naive T cells, and regulatory T cells to secondary lymphoid organs, facilitating immune surveillance, antigen presentation, and lymphocyte activation. CCR7 signaling is critical for initiating immune responses and maintaining lymphoid tissue architecture.
Recombinant CCR7 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, bioactive forms of the receptor. It often includes tags (e.g., His-tag or Fc-fusion) for ease of purification, detection, or functional studies. Researchers utilize CCR7 recombinant protein to investigate receptor-ligand interactions, signaling pathways (e.g., MAPK/ERK, PI3K/Akt), and its role in diseases. For example, aberrant CCR7 expression is linked to cancer metastasis (e.g., lymphoma, melanoma) and autoimmune disorders, making it a therapeutic target.
In drug discovery, CCR7 recombinant protein aids in screening inhibitors or modulators for immunotherapy. It also serves as a tool in studying immune cell migration in vitro (e.g., transwell assays) and optimizing cell-based therapies (e.g., enhancing DC vaccine efficacy). Its applications extend to structural biology for elucidating receptor conformations and ligand-binding mechanisms. Overall, CCR7 recombinant protein is indispensable for advancing both basic immunology research and translational clinical strategies.
×
